Markets:

Overview

News

Currencies

International

Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

78.71 -1.20 (-1.50%)

Streaming Delayed Price Updated: 10:13 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter ↗

May 27, 2025

Via Benzinga

1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of

May 23, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

May 22, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Value Stocks with Mounting Challenges

May 22, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

An Overview of ANI Pharmaceuticals's Earnings ↗

May 08, 2025

Via Benzinga

3 Small-Cap Stocks Walking a Fine Line

May 13, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

ANI Pharma Reports Upbeat Q1 Earnings, Revises Full-Year Outlook: Retail’s Pleased ↗

May 09, 2025

The CEO dismissed the impact of Trump tariffs, noting that the company produces a major portion of its goods in the U.S.

Via Stocktwits

Topics Government World Trade

Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact ↗

May 09, 2025

ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth.

Via Benzinga

ANI Pharmaceuticals (NASDAQ:ANIP) Reports Strong Q1, Full-Year Outlook Slightly Exceeds Expectations

May 09, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 43.4% year on year to $197.1 million. The...

Via StockStory

Earnings Scheduled For May 9, 2025 ↗

May 09, 2025

Via Benzinga

Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow

May 08, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be announcing earnings results tomorrow before market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

April 28, 2025

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 of Wall Street’s Favorite Stock to Target This Week and 2 to Keep Off Your Radar

April 27, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

April 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings?

April 15, 2025

Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by...

Via StockStory

Topics Stocks Supply Chain

Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

April 11, 2025

Via Benzinga

3 Russell 2000 Stocks in the Doghouse

April 02, 2025

Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment

March 18, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts ↗

March 14, 2025

Via Benzinga

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Growth Stock to Target This Week and 2 to Avoid

March 12, 2025

Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID...

Via StockStory

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today

February 28, 2025

Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly...

Via StockStory

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast ↗

February 28, 2025

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.

Via Benzinga

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 28, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars

February 28, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year...

Via StockStory

Earnings Scheduled For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

February 21, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

February 19, 2025

Via StockStory

Topics Artificial Intelligence Intellectual Property

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

February 14, 2025

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.